Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Wins Funding For Second Histology-Independent Drug In England

Executive Summary

Patients in England with NTRK fusion-positive solid tumors will now have access to another cutting-edge cancer treatment that can be used to treat tumors regardless of where in the body they originated.

You may also be interested in...



English Funding Success For Roche’s Rozlytrek In NSCLC

English patients with advanced NSCLC now have another NHS treatment option in the form of Roche’s entrectinib.

English Funding Success For Roche’s Rozlytrek In NSCLC

English patients with advanced NSCLC now have another NHS treatment option in the form of Roche’s entrectinib.

EU Approvals In Sight For Novartis, Roche, and Janssen

EU approval is a formality for the eight products given the nod this week at the European Medicines Agency. There's no word, though, on filgotimid, from Gilead/Galapagos.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel